Table I.
Baseline Characteristics for the Pooled Analysis Safety Population
| Irbesartan/HCTZ (n=796) | Irbesartan (n=335) | HCTZa (n=104) | |
|---|---|---|---|
| Age (range), y | 53.4 (23–87) | 53.7 (25–87) | 56.0 (21–83) |
| Male sex, % | 57.6 | 51.6 | 59.6 |
| White race, % | 83.7 | 85.6 | 82.7 |
| Black race, % | 14.7 | 12.8 | 14.4 |
| Weight (range), kg | 88.8 (46.0–164.3) | 90.7 (44.0–151.5) | 88.4 (55.0–146.1) |
| Baseline DBP (range), mm Hg | 106.8 (66.0–131.6) | 108.4 (74.3–135.0) | 97.6 (74.7–110.7) |
| Baseline SBP (range), mm Hg | 167.5 (127.7–221.7) | 168.4 (135.7–220.7) | 162.0 (136.0–180.0) |
| Baseline heart rate (range), bpm | 76.6 (48.0–111.0) | 76.2 (52.0–117.0) | 76.6 (50.0–108.0) |
| Medical history, % | |||
| Diabetes | 12.4 | 13.1 | 12.5 |
| Hyperlipidemia | 38.2 | 36.7 | 35.6 |
| Stable angina pectoris | 2.3 | 4.2 | 1.0 |
| Stroke or transient ischemic attack | 1.5 | 2.1 | 1.0 |
| Myocardial infarction | 1.4 | 1.2 | 1.9 |
| Previous antihypertensive therapy | 52.0 | 56.7 | 45.2 |
| aStudy 2 (patients with moderate blood pressure) only. Abbreviations: bpm, beats per minute; DBP, diastolic blood pressure; HCTZ, hydrochlorothiazide; SBP, systolic blood pressure. | |||